Market Analysis of Overactive Bladder Treatment Approaches | Key Companies- Urovant Sciences, Bayer, Taiho Pharmaceuticals, and Others

The Overactive Bladder market report provides current treatment practices, emerging drugs, Overactive Bladder market share of the individual therapies, current and forecasted Overactive Bladder market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Overactive Bladder treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Overactive Bladder market.

Recent Developmental Activities in the Overactive Bladder Treatment Landscape

• BAY 1817080 is a purinergic P2X3 receptor antagonist being developed by Bayer to treat persistent overactive bladder. Phase II clinical trials were initiated by Bayer for BAY 1817080 in September 2020 to determine how well the drug BAY1817080 works in Overactive Bladder patients with urgency urinary incontinence (UUI).

• TAC-302, an orally bioavailable drug, stimulates neurite outgrowth activity in cultured peripheral neurons and has beneficial effects on bladder denervation and storage/voiding dysfunctions. TAC-302 is being developed by Taiho Pharmaceutical. The company has completed Phase II study to evaluate the efficacy and safety of TAC302 in detrusor underactivity patients to treat overactive bladder.

• Urovant Sciences investigational novel gene therapy, URO-902, investigated in a phase IIa, randomized, double-blind, placebocontrolled, multicenter trial to evaluate the efficacy, safety, and tolerability of a single physician-administered dose of a novel gene therapy for patients with overactive bladder (OAB) who have not been adequately managed with oral or transdermal pharmacologic therapy for OAB. Urovant Sciences has recently presented interimdata from Phase IIa study supporting safety, tolerability, and efficacy endpoints at 2022 American Urological Association Meeting.

To Know in detail about the Overactive Bladder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Overactive Bladder Market Insights- https://www.delveinsight.com/sample-request/overactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Overactive Bladder Overview
Overactive bladder (OAB) is a condition where there is a frequent feeling of needing to urinate to adegree that it negatively affects a person's life. The frequent need to urinate may occur during the day,at night, or both. If there is loss of bladder control then it is known as urge incontinence. More than40% of people with overactive bladder have incontinence. Conversely, about 40% to 70% of urinaryincontinence is due to overactive bladder.

Key Takeaways from the Overactive Bladder Market Report

• The Overactive bladder market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• The Prevalent Cases of Overactive Bladder is higher in females than in males.

• The Overactive Bladder Companies include Urovant Sciences, Bayer, Taiho Pharmaceutical, Kyorin Pharmaceutical Co. Ltd, Novartis, Astellas Pharma Inc, Lee's Pharmaceutical Limited, Ono Pharmaceuticals Co. Ltd, and others.

• Promising Overactive Bladder Pipeline Therapies include TAC-302, BAY 1817080, URO-902, GEMTESA (vibegron), Solifenacin succinate, Darifenacin, Imidafenacin, KRP-197/ONO-8025, Tolterodine Extended-release Tablet, Tamsulosin, Mirabegron, Fesoterodine, and others

Overactive Bladder Epidemiology Segmentation in the 7MM
• Total Overactive Bladder Prevalent cases
• Overactive Bladder Gender-specific Prevalent Cases
• Overactive Bladder Type-specific Prevalent Cases
• Overactive Bladder Diagnosed and Treatable Cases

Download the report to understand which factors are driving Overactive Bladder epidemiology trends @ Overactive Bladder Epidemiological Insights- https://www.delveinsight.com/sample-request/overactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Overactive Bladder Market Insights
Overactive bladder is a complex of symptoms that generally do not affect survival, but may compromisequality of life. For this reason, physicians should carefully weigh the potential benefit of a particular treatmentagainst the risk, severity, and reversibility of adverse effects.

Overactive Bladder Market Forecast
The FDA has recently approved vibegron (Gemtesa) for the treatment of adult patients with overactivebladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency inDecember2020. Hence, if first-line therapies and medications fail to provide relief, there are minimally invasive treatments likebotox injections, sacral neuromodulation (SNM), and percutaneous tibial nerve stimulation (PTSN), have beenshown to reduce severe OAB symptoms by 80% to 90%. In rare cases, augmentation cystoplasty or urinary diversion may be considered in patients with severe,refractory, complicated overactive bladder. Indwelling catheters (e.g., transurethral, suprapubic) are notrecommended as a management strategy for overactive bladder except as a last resort in select patients.

Find out more about the Overactive Bladder Pipeline Segmentation, Therapeutics Assessment, and Overactive Bladder Emerging Drugs @ Overactive Bladder Treatment Landscape- https://www.delveinsight.com/sample-request/overactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Overactive Bladder Market Report

• Coverage- 7MM

• Overactive Bladder Companies- Urovant Sciences, Bayer, Taiho Pharmaceutical, Kyorin Pharmaceutical Co. Ltd, Novartis, Astellas Pharma Inc, Lee's Pharmaceutical Limited, Ono Pharmaceuticals Co. Ltd, and others.

• Overactive Bladder Pipeline Therapies- TAC-302, BAY 1817080, URO-902, GEMTESA (vibegron), Solifenacin succinate, Darifenacin, Imidafenacin, KRP-197/ONO-8025, Tolterodine Extended-release Tablet, Tamsulosin, Mirabegron, Fesoterodine, and others.

• Overactive Bladder Market Dynamics: Overactive Bladder Market Drivers and Barriers

• Overactive Bladder Market Access and Reimbursement, Unmet Needs

Dive deep into rich insights for drugs for Overactive Bladder Pipeline Companies and Therapies, click here @ Overactive Bladder Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/overactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Overactive Bladder
3. Competitive Intelligence Analysis for Overactive Bladder
4. Overactive Bladder: Market Overview at a Glance
5. Overactive Bladder: Disease Background and Overview
6. Patient Journey
7. Overactive Bladder Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Overactive Bladder Unmet Needs
10. Key Endpoints of Overactive Bladder Treatment
11. Overactive Bladder Marketed Products
12. Overactive Bladder Emerging Therapies
13. Overactive Bladder: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Overactive Bladder
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Got Queries? Find out the related information on Overactive Bladder Mergers and acquisitions, Overactive Bladder Licensing Activities @ Overactive Bladder Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/overactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.